March 2026, Vol 7, No 1

A US real-world claims database analysis demonstrated that durvalumab plus gemcitabine and cisplatin improves survival in patients with advanced biliary tract cancer.

Real‑world outcomes show survival benefit of first-line durvalumab or pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Tinengotinib, a novel FGFR inhibitor, has the potential to overcome resistance to prior FGFR therapies in the treatment of advanced cholangiocarcinoma.

FGFR2 inhibition with lirafugratinib delivers strong responses and manageable safety in FGFR2‑altered advanced cholangiocarcinoma.

A post-hoc analysis of HERIZON-BTC-01 demonstrates improved survival outcomes in patients utilizing zanidatamab.

Ivosidenib in combination with durvalumab plus gemcitabine and cisplatin shows potential activity with minimal toxicity in patients with IDH1‑mutant cholangiocarcinoma.

Real‑world data in IDH1‑mutant cholangiocarcinoma illuminates biomarker testing trends, treatment sequencing, and survival outcomes, outlining the role of ivosidenib in second‑line care.

Adjuvant sintilimab plus capecitabine shows promising recurrence‑free survival and manageable safety in resected extrahepatic cholangiocarcinoma.

The Cholangiocarcinoma Foundation (CCF) is thrilled to announce the upcoming 13th Annual Cholangiocarcinoma Foundation Conference, set to take place in Salt Lake City, UT, from May 1-3, 2026, with a virtual option also available.